Author

A. Gras

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

B. K. Gautam· 2 shared B. Tinsley· 2 shared E. Benzie· 2 shared E. K. Wagner· 2 shared J. F. Simons· 2 shared J. Leong· 2 shared J. Saini· 2 shared K. P. Carter· 2 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

B. K. Gautam

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Lack of blocking activity in anti-CTLA-4 antibodies reduces toxicity, but not anti-tumor efficacy

E. L. Stone, K. P. Carter, E. K. Wagner, M. A. Asensio, E. Benzie, Y. Y. Chiang, G. L. Coles, C. Edgar, B. K. Gautam, A. Gras, J. Leong, R. Leong, V. A. Manickam, R. A. Mizrahi, A. Niedecken, , D. S. Johnson

This study shows that anti-CTLA-4 antibodies with reduced checkpoint inhibition have better anti-tumor efficacy and lower toxicity by primarily depleting tumor-infiltrating Tregs via FcR signaling.

bioRxiv · Jul 12, 2021 · PreprintImmunology

Capturing and Recreating Diverse Antibody Repertoires as Multivalent Recombinant Polyclonal Antibody Drugs

S. M. Keating, R. A. Mizrahi, M. S. Adams, M. A. Asensio, E. Benzie, K. P. Carter, Y. Chiang, R. C. Edgar, B. K. Gautam, A. Gras, J. Leong, R. Leong, Y. W. Lim, V. A. Manickam, A. V. Medina-Cucurella, , E Meyer

This paper demonstrates a technology to capture and recreate diverse antibody repertoires as multivalent recombinant drugs, showing applications against SARS-CoV-2, Zika virus, and graft-versus-host disease.

bioRxiv · Aug 5, 2020 · PreprintImmunology